Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized study comparing the incidence of acute clinical or subclinical rejection with two dosing regimens of CellCept in de novo renal transplant recipients receiving induction, cyclosporine and brief steroid therapy

Next Previous
X
Search
Trial Profile

A randomized study comparing the incidence of acute clinical or subclinical rejection with two dosing regimens of CellCept in de novo renal transplant recipients receiving induction, cyclosporine and brief steroid therapy

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Nov 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mycophenolate mofetil (Primary) ; Methylprednisolone
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms OPERA
  • Sponsors Roche

    • Most Recent Events

    • 06 Dec 2013 New source identified and integrated (ClinicalTrials.gov; NCT02005562).
    • 30 Aug 2009 Results presented at the 14th Congress of the European Society for Organ transplantation.
    • 30 Aug 2009 Pharmacokinetic data pertaining to mycophenolic exposure reported at the 14th Congress of the European Society for Organ transplantation.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top